JOURNAL OF THE CZECH PEDIATRIC SOCIETY AND THE SLOVAK PEDIATRIC SOCIETY

Čes-slov Pediat 2022, 77(Suppl.3):S18-S23 | DOI: 10.55095/CSPediatrie2022/054

Current perspectives on the aetiology of tall stature in children and adolescents (2): Non-syndromic tall statureComprehensive Report

Kateřina Adamovičová, Lukáš Plachý, Jan Lebl, Stanislava Koloušková, Štěpánka Průhová
Pediatrická klinika, 2. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice v Motole

Non-syndromic tall stature can be caused by growth hormone overproduction, hyperthyroidism, obesity, hypogonadism, precocious puberty or as constitutional growth acceleration. There are conditions caused by a genetic cause as well such as non-sydromic tall stature, typically familial tall stature or, more rarely, pituitary gigantism, which includes X-linked acrogigantism (XLAG). Tall stature can r arely occur in neurofibromatosis type I or in glucocorticoid resistance. After excluding the common endocrinopathies the patients are, in clinical practice, assigned as "familial tall stature" or "constitutional growth acceleration". Recently, there have been findings showing that non-syndromic tall stature can be caused by a monogenic cause, which can only be found by detailed genetic testing wit h precise clinical-genetic evaluation.

Keywords: tall stature, growth hormone overproduction, FIPA, XLAG, familial tall stature

Published: November 4, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adamovičová K, Plachý L, Lebl J, Koloušková S, Průhová Š. Current perspectives on the aetiology of tall stature in children and adolescents (2): Non-syndromic tall stature. Ces-slov Pediat. 2022;77(Suppl.3):S18-23. doi: 10.55095/CSPediatrie2022/054.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Meazza C, Gertosio C, Giacchero R, et al. Tall stature: a difficult diagnosis? Ital J Pediatr 2017;43(1):66. Go to original source... Go to PubMed...
    2. Albuquerque E, Scalco RC, Jorge A. Management of endocrine disease: Diagnostic and therapeutic approach of tall stature. Eur J Endocrinol 2017; 176(6): 339-353. Go to original source... Go to PubMed...
    3. Leung AKC, Leung AAC, Hon KL. Tall stature in children. Adv Pediatr 2019; 66: 161-176. Go to original source... Go to PubMed...
    4. Wei C, Gregory JW. Physiology of normal growth. Paediatrics Child Health 2009; 19(5): 236-240. Go to original source...
    5. Baron J, Sävendahl L, De Luca F, et al. Short and tall stature: a new paradigm emerges. Nat Rev Endocrinol 2015; 11(12): 735-746. Go to original source... Go to PubMed...
    6. Lazarus JE, Hegde A, Andrade AC, et al. Fibroblast growth factor expression in the postnatal growth plate. Bone 2007; 40(3): 577-586. Go to original source... Go to PubMed...
    7. Liu Z, Lavine KJ, Hung IH, Ornitz DM. FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Dev Biol 2007; 302(1): 80-91. Go to original source... Go to PubMed...
    8. Mancilla EE, De Luca F, Uyeda JA, et al. Effects of fibroblast growth factor-2 on longitudinal bone growth. Endocrinology 1998; 139(6): 2900-2904. Go to original source... Go to PubMed...
    9. Hung IH, Yu K, Lavine KJ, Ornitz DM. FGF9 regulates early hypertrophic chondrocyte differentiation and skeletal vascularization in the developing stylopod. Developmen Biol 2007; 307(2): 300-313. Go to original source... Go to PubMed...
    10. Nilsson O, Parker EA, Hegde A, et al. Gradients in bone morphogenetic protein-related gene expression across the growth plate. J Endocrinol 2007; 193(1): 75-84. Go to original source... Go to PubMed...
    11. De Luca F, Barnes KM, Uyeda JA, et al. Regulation of growth plate chondrogenesis by bone morphogenetic protein-2. Endocrinology 2001; 142(1): 430-436. Go to original source... Go to PubMed...
    12. Hannema SE, van Duyvenvoorde HA, Premsler T, et al. An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities. J Clin Endocrinol Metab 2013; 98(12): 1988-1998. Go to original source... Go to PubMed...
    13. Miura K, Kim OH, Lee HR, et al. Overgrowth syndrome associated with a gain-of-function mutation of the natriuretic peptide receptor 2 (NPR2) gene. Am J Med Genet A 2014; 164 A (1): 156-163. Go to original source... Go to PubMed...
    14. Chan Y, Holmen OL, Dauber A, et al. Common variants show predicted polygenic effects on height in the tails of the distribution, except in extremely short individuals. PLoS Genet 2011; 7(12): e1002439. Go to original source... Go to PubMed...
    15. Plachy L, Dusatkova P, Maratova K, et al. Familial short stature-a novel phenotype of growth plate collagenopathies. J Clin Endocrinol Metabolism 2021; 106(6): 1742-1749. Go to original source... Go to PubMed...
    16. Corredor B, Dattani M, Gertosio C, Bozzola M. Tall stature: a challenge for clinicians. Curr Pediatr Rev 2019; 15(1): 10-21. Go to original source... Go to PubMed...
    17. Vasilev V, Daly AF, Trivellin G, et al. Hereditary endocrine tumours: current state-of-the-art and research opportunities: The role of AIP and GPR101 in familial isolated pituitary adenomas (FIPA). Endocr Rel Cancer 2020; 27(8): T77-T86. Go to original source... Go to PubMed...
    18. Beckers A, Petrossians P, Hanson J, Daly AF. The causes and consequences of pituitary gigantism. Nat Rev Endocrinol 2018; 14(12): 705-720. Go to original source... Go to PubMed...
    19. Cannavo S, Ragonese M, Puglisi S, et al. Acromegaly is more severe in patients with AHR or AIP gene variants living in highly polluted areas. J Clin Endocrinol Metab 2016; 101(4): 1872-1879. Go to original source... Go to PubMed...
    20. Daly AF, Lysy PA, Desfilles C, et al. GHRH excess and blockade in X-LAG syndrome. Endocr Rel Cancer 2016; 23(3): 161-170. Go to original source... Go to PubMed...
    21. Beckers A, Lodish MB, Trivellin G, et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Rel Cancer 2015; 22(3): 353-367. Go to original source... Go to PubMed...
    22. Pagani S, Radetti G, Meazza C, Bozzola M. Analysis of growth hormone receptor gene expression in tall and short stature children. J Pediatr Endocrinol Metab 2017; 30(4): 427-430. Go to original source... Go to PubMed...
    23. Carmi D, Shohat M, Metzker A, Dickerman Z. Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics 1999; 103(6): 1257-1262. Go to original source... Go to PubMed...
    24. Meimaridou E, Hughes CR, Kowalczyk J, et al. Familial glucocorticoid deficiency: New genes and mechanisms. Mol Cell Endocrinol. 2013; 371(1-2): 195-200. Go to original source... Go to PubMed...
    25. Savage MO, Lebrethon MC, Blair JC, et al. Growth abnormalities associated with adrenal disorders and their management. Horm Res 2001; 56 Suppl 1: 19-23. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content